

CURRICULUM VITAE

INVESTIGATOR NAME: Moira Alejandra Reig
INVESTIGATOR NACIONALITY: Argentine
LICENSE NUMBER: 93754
STUDY LOCATION ADDRESS: **Centro de Investigaciones Médicas Mar del Plata**
Av. Colón 3083 1°, 4°, 5° and 7° floor. B7600FYK Mar del Plata, Bs. As.
Argentina.
Tel. 0223-4917628/ Fax 0223-4957241

EDUCATION: List Colleges/ Universities attended with dates and degrees obtained

2000 Facultad de Ciencias Médicas de la Universidad Nacional de La Plata
Degree: Physician

POSTGRADUATE TRAINING: list Specialties, give dates, names of institutions:

2000-2003 Resident of internal medicine. Hospital Municipal de Agudos. "Dr. Arturo Illia". Villa Gesell
2003 External Rotation. Centro de Atención primaria de Salvador Pau y Manises. Valencia, España.
2004 Chief of internal medicine residency. Hospital Municipal de Agudos. Villa Gesell.
-Training Certificated Of Good Clinical Practice (GCP). FEFYM. November 2016
-Training in Ethics of the research. Conducted by Dr. Ignacio Maglio. Aug 2017
-Sep 2018- Course of Ethics and Good Clinical Research Practices. Ministerio de Salud de la Nación, duration 80 hs
-Oct 2020 Good Clinical Research Practice NIDA
-Sep 2023- Good Clinical Research Practices NIDA Clinical Trials Network

PROFESSIONAL EXPERIENCE:

- Board certification / Name of board:

2000 Physician. Granted by Universidad Nacional de La Plata.

. Previous appointments (List positions held, gives dates and institutions):

1995 Practitioner guard. Hospital Gutierrez. La Plata
1996-1997 Practitioner guard. Hospital Zonal General de Agudos "San Roque". Gonnet, La Plata.
1998 Pre grade student residency. Hospital Interzonal General de Agudos y Hospital Interzonal Materno Infantil. Mar del Plata
2000-2003 Internal Medicine residency. Hospital Municipal de Agudos "Dr. Arturo Illia". Villa Gesell
2003 Guard physician. Clínica Privada del Sol. Villa Gesell.
2003 External rotation. Centro de Atención primaria de Salvador Pau y Manises. Valencia. España
2003-2004 Physician on duty at serve the dialysis Hospital Municipal de Madariaga
2004-2006 Physician beneficiaries INSSJyP. Hospital Privado de Comunidad. Mar del Plata.
2004 Chief of general medicine residency. Hospital Municipal de Agudos. Villa Gesell

. Present appointment

Since 2014 Medical Staff of Centro de Investigaciones Médicas Mar del Plata
Since 2007 Physician. Private practice. Mar del Plata
Since 2008-2014. Clinical Medicine, staff of Centro de Investigaciones Médicas. Clínica de Fracturas y Ortopedia. Mar del Plata.
Since 2014 Staff of Centro de Investigaciones Médicas Mar del Plata

PROFESSIONAL EXPERIENCE IN CLINICAL INVESTIGATION:

CZOL446M2309 Phase III Osteoporosis. Since 2007. Sub Investigator.
ROCKET Phase III. Atrial fibrillation. 2007-2010. Sub Investigator.
EFC10342 HIP 1 Hip replacement. 2008-2009. Sub Investigator.
EFC10343 HIP 2 Hip fracture. 2008-2009. Sub Investigator.
EFC10571 Knee Knee replacement. 2008-2009. Sub Investigator.
RADIUS Phase II Osteoporosis in woman. 2007-2009. Sub Investigator.

CRESCENDO Phase III Cardiovascular risk. 2007-2008. Sub Investigator.
D1680C0002 Phase IIIb. 2008-2009. Sub Investigator.
BI 1218.18 Phase III. 2008-2009. Sub Investigator.
GETGOAL X Diabetes. 2008-2011 Sub Investigator.
CLAF 23137 Bad controlled diabetes with renal failure. Since 2008. Sub Investigator.
BC21713 Diabetes. Since 2009. Sub Investigator.
RAD 00-001 Observational study. Hot flashes. 2008-2009. Sub Investigator.
RAD1901002 Hot flashes. 2008-2009. Sub Investigator.
BI1245.9 Phase II Diabetes. Since 2009 Sub. Investigator.
BI1245.10 Phase II Diabetes. Since 2009. Sub Investigator.
BOREALIS Phase III Atrial fibrillation. 2008-2010 Sub. Investigator.
ATLAS II Phase II Acute coronary syndrome. Since 2009. Sub Investigator.
DAPA 10 Phase IIIb Diabetes. Since 2010-2012. Sub Investigator.
CACZ Phase IIb y III Diabetes. Since 2010-2011. Sub Investigator.
DIA3008 Phase III Diabetes. Since 2010-2017. Sub Investigator.
AFICIONADO Phase IV. Diabetes. Since 2010-2014 Sub Investigator.
TECOS Phase III. Diabetes. Since 2010-2014. Sub Investigator.
FOREST Phase III. Diabetes. Since 2010-2012. Sub Investigator.
HOKUSAI Phase III. TVP/EP. 2010-2012 Sub. Investigator.
D1680C0003 Phase IV. Since 2010-2011. Sub Investigator.
CHIESI Phase III Epop. Since 2010-2012. Sub investigator.
ADC113874 Phase III. Epop. Since 2011-2013 Sub. investigator.
PEGASUS Phase III. Since 2010-2014 Sub Investigator.
CLCZ696B2314 Phase III. Since 2011.-2014 Sub Investigator.
EFC11319 Phase III. Since 2011-2013. Sub Investigator.
IMAGINE 2 Phase III. Diabetes. Investigator.
D5896C00027 Phase IV Asthma. Since 2012. Sub Investigator.
HZC113782 Phase III Epop. Since 2012. Sub Investigator.
HZA106853 Phase III Epop. Since 2012. Sub Investigator.
SAS115358 Fase IIIb. Asthma in Children. Since 2013-2016. Sub Investigator.
CQAB149B2401 Phase III Epop. Since 2012-2014. Sub Investigator.
B3D-EW-GHDW Phase IV Osteoporosis. Since 2012-2017. Sub Investigator.
EUCLID Phase IIIb Peripheral vascular disease. Since 2013-2016 Investigator.
CANTOS Acute myocardial infarction. Since 2013-2017 Sub Investigator.
ODYSSEY Phase IIIb. Acute coronary syndrome. Since 2013-2018 Sub Investigator.
JADZ Phase III Rheumatoid Arthritis. Since 2013-2015. Sub Investigator
JADV Phase III Rheumatoid Arthritis. Since 2013-2015. Sub Investigator
DIA3011 Phase III. Diabetes type II. Since 2013-2015. Sub Investigator.
CALIMA-D3250C00018. Phase III. Uncontrolled asthma. Since 2014-2016. Sub Investigator
MEDIVECTOR Phase III. Not complicated influenza. Since 2014-2015. Sub Investigator
AMGEN20110142. Phase III. Osteoporosis. Since 2014-2017. Sub Investigator
B12610007 Phase III. Diabetic nephropathy. Since 2014-2015. Sub Investigator
DECLARE Phase IIIb. Diabetes type II and cardiovascular risk. Since 2014-2018. Sub Investigator
CQVA Phase III. Epop. Since 2014-2016 Sub Investigator
3251C00021 BORA Phase III COPD 2015-2016 Sub investigator
MK-018. Phase III. Diabetes type II and cardiovascular risk. Since 2014-2016. Sub Investigator.
NN-95353626. Phase IIIa. Diabetes type II and Metformina failure. Since 2014-2016. Sub Investigator
DIA4003. Phase III. Diabetes II and cardiovascular risk. Since 2014-2017 Sub Investigator.
JADY. Phase III. Rheumatoid arthritis. Since 2015. Sub Investigator
BCB109 Phase III Diabetes II. Since 2014-2017 Sub Investigator
MK 8835-001. Phase III .Diabetes Since 2015 to 2016. Sub Investigator
MK 8835-005. Phase III. Diabetes. Since 2015 to 2016. Sub Investigator
HARMONY. Phase III/IV. Diabetes with cardiovascular events. Since 2015-2018. Sub Investigator
CTT116855 fase III, COPD 2015-2017 Sub Investigator
ABBVIE M11-352. Phase III Kidney failure and diabetes. Since 2015-2018 Sub Investigator
D513BC00001THEMIS. Phase III. Diabetes with cardiovascular risk. Since 2015-2019. Sub Investigator
GEMINI. Phase III. Cardiovascular event 2016-2017. Sub Investigator
TERRANOVA. Phase III. COPD. Since 2015-2018 Sub Investigator.
MARINER Phase III. Risk of venous thromboembolism at discharge. Since 2015-2017. Sub Investigator
CV185316 AUGUSTUS. Phase IV. Atrial fibrillation and acute coronary syndrome. Since 2016-2019 Sub

Investigator

AP611074 CT4. Phase II. Condyloma. Since 2016-2018. Sub Investigator
OLYMPUS. Phase III. Chronic Renal Failure with Anemia. Since 2016 -2019 Sub Investigator
CREDENCE. Phase III. Chronic Renal Failure with diabetes Since 2016-2018 Sub Investigator
VOYAGER. Phase III. Risk of thrombotic vascular events. Since 2016 Sub Investigator
GA 28949. Phase III.. Moderate to severe ulcerative colitis Since 2017. Sub Investigator
GA 28951. Phase II/III Extensión. Moderate to severe ulcerative colitis. Since 2017 Sub Investigator
PT010005 Phase III COPD. Since 2017. Sub Investigator.
PT009003 SOPHOS. Phase III COPD. Since 2017-2018. Sub investigator
MK0431-848. Phase III DBT 2. Since 2017-2018. Sub Investigator
MK0431/845 Phase III. DBT 2. Since 2017-2018 Sub. Investigator
MK8835-004-01/B1521021. Phase III Diabetes 2 with established vascular disease Since 2017. Sub Investigator.
ASCEND-200808 Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub Investigator .
AKB-6548-CI-0015. Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub Investigator
AKB-6548-CI-0014. Phase III. Anemia associated with chronic kidney disease. Since 2017 Sub Investigator
DAPA CKD- D169AC00001. Phase III. Chronic renal disease. Since 2017. Sub Investigator
DAPA HF D1699C00001. Phase III. Chronic heart failure with reduced ejection fraction. 2017 Sub Investigator
MNK4049. Phase III. Focal and segmental sclerosis. Since 2017 Sub Investigator
MLN0002SC-3030 Phase IIIb ulcerative colitis Since 2017-2018 Sub Investigator
MLN0002SC-3031 Phase III. ulcerative colitis Since 2017-2018 Sub Investigator
PROMINENT. Phase III. Cardiovascular disease, triglyceride reduction in diabetic patients. Since 2017. Sub Investigator
ETC1002-043CLEAR OUTCOMES. Phase III. Intolerance to statins with cardiovascular risk. Since 2017. Sub Investigator
GA29350 Phase II Rheumatoid arthritis.. Since 2017. Sub Investigator
GA30067 extention Phase II Rheumatoid arthritis.. Since 2018 Sub Investigator.
BI1245.110. Phase III.. Chronic heart failure with preserved ejection fraction . Since 2018. Sub Investigator
BI 1245.121. Phase III Chronic heart failure with reduced ejection fraction. Since 2018. Sub Investigator
EFC14875. SCORED Phase III Cardiovascular and renal events in patients with DBT II, cardiovascular risk factors and moderate failure. Since 2018. Sub Investigator
EFC14837 Phase III Diabetes with moderate renal disease. Since 2018 Sub Investigator
EFC15116 Phase III Diabetes with severe kidney disease. Since 2018 Sub Investigator
CREDO 2 / CLO4041023. Phase III Rheumatoid arthritis. Since 2018. Sub Investigator
CREDO 3 / CLO4041025. Phase III Rheumatoid arthritis. Since 2018 Sub Investigator
205270 Phase III Anemia associated with chronic kidney disease. Since 2018. Sub Investigator
HZA107116. Phase III Astma in children 5 to 17 years old. Since 2018 Sub investigator
204837 Phase III. Dialysis patients with anemia related to chronic kidney disease. Since 2018. Sub Investigator
CREDO 4/CLO041024. Phase III Rheumatoid arthritis Since 2019 Sub investigator
RLM-MD-02 Phase III diabetic gastroparesis. Since 2009 Sub investigator
RLM-MD-03 Extensión Phase III diabetic gastroparesis. Since 2009 Sub investigator
RLM-MD-04 Phase III diabetic gastroparesis. Since 2009 Sub investigator
DELIVER Phase III Chronic heart failure with preserved ejection fraction . Since 2019 Sub Investigator
BOREAS Fase III. EPOC. Desde 2020. Sub Investigador
CONTRAST 1 201790- Phase III Artritis reumatoidea. Since 2020 Sub Investigador
CONTRAST 2 202018- Phase III Artritis reumatoidea. Since 2020 Sub Investigador
CONTRAST X- (extension) Phase III Rheumatoid Arthritis. Since 2020 Sub Investigator
TRICIDA, Fase IIIb Acidosis Metabólica. Desde 2019 Sub Principal
PLATFORM PACRD2001- Phase II Crohn's Disease Sub Investigator Since 2020
QUASAR CNTO1959UCO3001 Phase IIb/III Ulcerative colitis. Sub Investigator Since 2020
NODE 303. Phase III. Paroxysmal Supraventricular tachycardia. Sub Investigator. Since 2020
MIT-Do001-C301(Estetra) Phase III. Post menopausal woman with vasomotor symptoms. Sub Investigator. Since 2020
MATINEE Phase IIIA. COPD with eosinophilic levels. Since 2021. Sub Investigator

AMETHYST Phase II. Heart failure with preserved EF. Since 2021. Sub Investigator
AMEERA-5 Phase III. Breast cancer Since 2021. Sub Investigator
213400 Phase III Non-small cell lung cancer. Since 2021 Sub Investigator
ARENA APD334-202 Phase III. Crohn's disease. Since 2021 Sub Investigator
MEDI3506 Phase IIb. Diabetic nephropathy. Since 2021 Sub Investigator
1366,0002 Phase III Non-diabetic kidney disease. Since 2021 Sub Investigator
1366,0005 Phase III Diabetic chronic kidney disease. Since 2021 Sub Investigator
CC-93538-EE-01 Phase III Eosinophilic esophagitis. Since 2021 Sub Investigator
ANJ900D3501 Phase III Diabetes with variable renal function. Since 2021. Sub Investigator
D7551C00001 Phase IIb. Chronic proteinuric kidney disease. Since 2021 Sub Investigator
DIALIZE Phase III Arrhythmia in patients on chronic hemodialysis due to recurrent hyperkalemia. Since 2021 Sub Investigator
INS1007-301 ASPEN Phase III Bronchiectasis. Since 2021 Sub Investigator
GKPTN Platform Study. Since 2021 Sub Investigator
TACKLE Phase III Treatment of Covid in non-hospitalized adult patients. Since 2021 Sub Investigator
KANGTAI Phase III Covid-19 Vaccine Since 2021 Sub-Investigator
BANNER Phase IIIA HIV Since 2021 Sub Investigator
RPC01-3201 Moderate to severe Crohn's disease From 2022 Sub Investigator
ZEUS Phase III Cardiovascular disease, chronic renal failure. Since 2022 Sub Investigator
ALIGN Phase III IgA nephropathy and progressive loss of renal function. Sub Investigator
STABILIZE Phase III Chronic kidney disease and hyperkalaemia From 2022. Sub Investigator
D4325C00001 ZENIT Phase IIB CKD with glomerular filtration rate between 20 and 60 ml/min/1.73 m2 Sub Investigator
PILASTER Phase III Epop and chronic bronchitis. Since 2021. Sub Investigator
GB4311 Phase IIb COPD. Since 2022 Sub-Investigator.
GO42784 LIDERA Phase III Breast cancer. Since 2022 Sub-Investigator
23OLE304 TOPAZ Phase III Lupus. Since 2022 Sub-Investigator
WILLOW Phase II Lupus erythematosus. Since 2022. Sub-Investigator
SURMOUNT I8F-MC-GPIJ Phase III Obesity. Since 2023. Sub-Investigator
RPC01-3204 Moderate to severe Crohn's disease. Since 2022 Sub-Investigator
RPC01-3203 Moderate to severe Crohn's disease. Since 2022 Sub-Investigator
CC-93538-EE-02 (Extension) Phase III Eosinophilic esophagitis. Since 2022 Sub-Investigator
BI 1378-0005 Chronic kidney disease. Since 2022. Principal Investigator
JASMINE 80202135SLE2001 Systemic Lupus Erythematosus (SLE) Since 2023. Sub Investigator
MS200569_0048 WILLOW LTE Phase II Lupus erythematosus Since 2023. Sub-investigator
J2A-MC-GZGU Phase III Adults with type 2 diabetes and inadequate glycemic control with Metformin. Since 2023 Sub investigator
23OLE301 (AMETHYST) Phase II Cutaneous lupus erythematosus. Since 2023 Sub Investigator
EX6018-4915 HERMES Phase III Patients with heart failure and inflammation. Since 2023 Sub Investigator
70033093AFL3002 LIBREXIA AFL Phase III Patients with Atrial Fibrillation Dede 2023 Sub Investigator
70033093ACS3003 LIBREXIA ACS Phase III Acute coronary syndrome. Since 2023 Subinvestigator
CR845-310302 KICK 2 Phase III ITCH OF MODERATE INTENSITY A
SEVERE IN SUBJECTS WITH CHRONIC KIDNEY DISEASE. Since 2023 Sub Investigator
ADVANCED
ACTIV-2b SCORPIO-HR Phase III Non-hospitalized patients with COVID-19 Since 2023 Sub-investigator
AT-03A-017 Phase III High-risk outpatients with COVID-19. Since 2023 Subinvestigator
209978 MARS-17 Phase II Osteoarthritis of the knee. Since 2023 Subinvestigator
AMG592 20170104 Phase II Moderate to severe ulcerative colitis. Since 2022 Subinvestigator
AMG592 20210210 EXT Phase II Moderate to severe ulcerative colitis. Since 2022 Subinvestigator
CNT01959UCA3004 ASTRO Phase III Moderately to severely active ulcerative colitis. Since 2023 Subinvestigator
K-001-201 Phase II NASH. Since 2023 Subinvestigator
BUS-P3-01 CALM Bellus Phase III Refractory chronic cough. Since 2023 Sub Investigator
EDP 938-104 ENANTA Phase IIb Acute syncytial respiratory virus. Since 2023 Subinvestigator
GB43374 OLE COPD Since 2023 Sub-researcher
CLI-06001AA1-04 PILASTER Phase III COPD Since 2023 Sub Investigator
CLI-06001AA1-05 PILAR Phase III COPD Since 2023 Sub Investigator

CLI-05993AA-06 TRITON Phase III COPD Since 2023 Sub Investigator
1368-0098 Phase IIb/III. Hidradenitis suppurativa. Since 2023 Sub Investigator
INCB 18424-319 Phase III Prurigo nodularis. Since 2023 Sub Investigator
77242113PSO3001 Phase III Moderate to severe plaque psoriasis. Since 2023 Sub Investigator
1366-0031 Phase II Cutaneous sclerosis. Since 2023 Sub Investigator
D6970C00002 BaxHTN Phase III Participants with Hypertension Uncontrolled on Two or More Medications including Participants with Resistant Hypertension Since 2024 Sub Investigator

MK 7240-001 CU Phase III participants with moderately to severely active ulcerative colitis Since 2024 SubInvestigator
219700 VOLITION Phase IIIb HIV-1 in antiretroviral therapy-naïve adults Sub Investigator Since 2024
23OLE306 (EMERALD) Phase III Systemic lupus erythematosus. Since 2024 Sub Investigator
D4325C00007 Chronic kidney disease and proteinuria. Since 2024 Sub Investigator
D7830C00004 FORTUNA Phase IIb. Non-alcoholic non-cirrhotic steatohepatitis with fibrosis (NASH) Since 2024 Sub Investigator
D4325C00010 ZENITH Phase III Chronic kidney disease and high proteinuria. Since 2024 Sub Investigator
MRXC-302 Phase III Moderate disease or severe diabetic foot infections. Since 2024 Sub Investigator
ACT17746 LIBERTY Phase II Ulcerative colitis with eosinophilic profile. Since 2024 Sub Investigator
78934804UCO2001 (DUET-UC) Phase IIb Moderately to severely active ulcerative colitis. Since 2024 Sub Investigator

DATE: 16 JAN 2024

INVESTIGATOR'S SIGNATURE:

Maira Reig
Medica
M.P. 93754